Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551.

Min, T; Wali, L; Williams, D M; Plummer, E; Gurung, A; Stephens, J W

Min, T; Wali, L; Williams, D M; Plummer, E; Gurung, A; Stephens, J W.

Afiliação

Min T; a Diabetes Research Group, School of Medicine, Swansea University , Swansea , Wales , UK.
Wali L; b Department of Diabetes & Endocrinology , ABM University Health Board , Swansea , Wales , UK.
Williams DM; b Department of Diabetes & Endocrinology , ABM University Health Board , Swansea , Wales , UK.
Plummer E; b Department of Diabetes & Endocrinology , ABM University Health Board , Swansea , Wales , UK.
Gurung A; b Department of Diabetes & Endocrinology , ABM University Health Board , Swansea , Wales , UK.
Stephens JW; b Department of Diabetes & Endocrinology , ABM University Health Board , Swansea , Wales , UK.

Curr Med Res Opin ; 33(9): 1715-1716, 2017 09.

Article em En | MEDLINE | ID: mdl-28562098

Assuntos

Nefropatias; Inibidores do Transportador 2 de Sódio-Glicose; Compostos Benzidrílicos; Glucose; Glucosídeos; Humanos; Sódio; Transportador 2 de Glucose-Sódio

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores do Transportador 2 de Sódio-Glicose / Nefropatias Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google